Country eligibility info

Australia - Third Countries

Check if partners from Australia qualify for Horizon Europe funding

Please note that this information sheet will be updated regularly and the list of countries divided into the different categories can always change over the period of Horizon Europe. If you are involving a partner from a non-EU country in your consortium please always check the status of this country in Horizon Europe at the moment of submission in the Horizon Europe Programme Guide.

Australia belongs to the group of Third Countries

Scroll further to find out what this means exactly

Specific remarks for Australia

This country provides co-funding modalities for its national organisations wishing to participate in Horizon Europe projects. You can find more details in this document.

Eligibility for Third Countries means...

Short explanation

Most Horizon Europe calls are open to participants from non-EU countries, also called Third Countries. If they are not automatically eligible for funding, they can still get funding in certain circumstances.

Specific third countries can also be excluded from participation to the programme or to a part of the programme  and/or to specific call topics mainly in order to safeguard the EU’s strategic assets, interests, autonomy or security. 

If a third country is allowed to participate but is not eligible for Horizon funding, then the organisations can still participate with own funding, and be included in the project as Associated partners.

A third country can participate as an associated partner with own funding. Associated partners have the following characteristics:

  • do not sign the grant agreement, thus cannot be a coordinator
  • must be registered in the participant register but will not be validated
  • need to be mentioned in the researchers table (organisation data) of part A in the application form
  • they have to indicate personmonths of their researchers
  • can be a subcontractor but cannot be a way to circumvent the general rules for participation
  • the L&F helpdesk of the European Commission has indicated that associated partners can act as work package leader in a Horizon Europe project
  • in the proposal the budget for the associated partners has to be filled out in the column “Financial contribution”. This budget will not be taken into account into the indicative budget of the proposal

Third countries can get exceptionally funding if

  1. they are identified in the call topic and/or work programme as being eligible for funding
  2. they are deemed essential for implementing the action in your proposal, for example in view of their:
  • outstanding competence/expertise
  • access to particular research infrastructures
  • access to particular geographical environments
  • access to particular data

Be aware that some third countries have created co-funding mechanisms which provide funding for the participants from their country in a successful submitted Horizon Europe proposal. In this document you will find an overview of the complementary funding of some third countries. The organisations of these countries participate as Associated Partners with own funding. 

All details regarding country eligibility is compiled in the infosheet “International cooperation".

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.